← 返回

SOCS1 是免疫稳态、炎症和肿瘤免疫中的关键检查点

英文原题:SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity.

查看英文原题

SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity.

PubMed 2024/06/14(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

细胞因子信号传导抑制因子(SOCS)家族蛋白是细胞因子信号传导的重要负调控因子。SOCS1 是 SOCS 家族的原型成员,在经典负反馈环路中发挥作用,抑制干扰素、白细胞介素-12 和白细胞介素-2 家族细胞因子所引发的信号传导。这些细胞因子在协调我们针对病毒病原体和癌症的免疫防御中发挥关键作用。SOCS1 限制细胞因子信号传导的能力使其成为一个重要的免疫检查点,在细胞因子驱动的炎症性和自身免疫性疾病患者中检测到有害的 SOCS1 变异体即证明了这一点。SOCS1 也已成为限制抗肿瘤免疫的关键检查点,既发挥肿瘤内在作用,也影响各种免疫细胞发起有效抗肿瘤反应的能力。在这篇综述中,我们描述 SOCS1 的作用机制,重点关注 SOCS1 在自身免疫和癌症中的作用,并讨论新的靶向 SOCS1 的癌症疗法的潜力,这些疗法可用于增强过继性免疫治疗和免疫检查点阻断。

展开英文摘要原文

The Suppressor of Cytokine Signaling (SOCS) family proteins are important negative regulators of cytokine signaling. SOCS1 is the prototypical member of the SOCS family and functions in a classic negative-feedback loop to inhibit signaling in response to interferon, interleukin-12 and interleukin-2 family cytokines. These cytokines have a critical role in orchestrating our immune defence against viral pathogens and cancer. The ability of SOCS1 to limit cytokine signaling positions it as an important immune checkpoint, as evidenced by the detection of detrimental SOCS1 variants in patients with cytokine-driven inflammatory and autoimmune disease.

SOCS1 has also emerged as a key checkpoint that restricts anti-tumor immunity, playing both a tumor intrinsic role and impacting the ability of various immune cells to mount an effective anti-tumor response. In this review, we describe the mechanism of SOCS1 action, focusing on the role of SOCS1 in autoimmunity and cancer, and discuss the potential for new SOCS1-directed cancer therapies that could be used to enhance adoptive immunotherapy and immune checkpoint blockade.

论文信息

作者
Bidgood GM、Keating N、Doggett K、Nicholson SE
单位
Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.Australia
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2024
原文标识
PubMed 38947335 · DOI 10.3389/fimmu.2024.1419951